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A high prevalence of psoriasis has been
reported in Norway, ranging from 4.8%
to 11.8% (Bo et al., 2008; Danielsen
et al., 2013; Kavli et al., 1985; Parisi
et al., 2013). Prevalence estimates
depend crucially on the validity of
questionnaires (Jagou et al., 2006; Kurd
and Gelfand, 2009; Lima et al., 2013;
Plunkett et al., 1999; Rea et al., 1976;
Wolkenstein et al., 2009). We aimed
to validate self-reported psoriasis in
a large population-based study in
Norway using clinical skin examination
performed by dermatologists as the
gold standard and also to estimate
the validation-based prevalence of
psoriasis in a general Norwegian
population.
Among adult participants of the third
survey of the Nord-Trøndelag Health
Study (HUNT3, 2006e8) (Krokstad
et al., 2013), we invited random sam-
ples of 150 with and 700 without self-
reported psoriasis, of whom 110 and
434 participated in the validation study,
respectively (see Supplementary
Figure S1 online). Validation was done
by comparing the result of the self-
reported question “Have you had or
do you have psoriasis?” in HUNT3 to
the outcome of the clinical interview
and extensive skin examination per-
formed by three dermatologists (EHM,IS, and MS). Because the diagnosis is
based on clinical signs and symptoms
(Boehncke and Schon, 2015), psoriasis
was defined as having a positive
history in combination with clinical
findings present at the day of skin ex-
amination. In cases of complete remis-
sion on examination day, diagnostic
confirmation had to be obtained either
from a previous medical record
collected from a dermatological clinic
or by a former skin biopsy. To obtain
estimates representative for the total
HUNT3 population, appropriate weights
were applied to account for differ-
ences in sampling probability. An
age-standardized prevalence estimate
according to the European standard
population distribution for adults > 20
years was calculated (Pace et al., 2013)
(see Supplementary Materials and
Methods online).
General characteristics of the 544
participants did not differ substantially
from the total HUNT3 study population
or from the nonresponders (see
Supplementary Tables S1 and S2 on-
line). Compared with all people with
self-report of psoriasis in HUNT3, par-
ticipants in the validation study re-
ported essentially similar characteristics
of their psoriasis but slightly more often
nail changes, psoriasis arthritis, and
having the diagnosis confirmed by adermatologist (see Supplementary
Table S3 online).
The overall self-reported prevalence
of psoriasis in HUNT3 was 5.8% (95%
confidence interval [CI], 5.6e6.0%),
and the validated prevalence was esti-
mated to 8.0% (95% CI, 6.4e9.9%)
(Table 1). Self-reported psoriasis had an
estimated sensitivity of 56% (95% CI,
44e68%), a specificity of 99% (95%
CI, 98e99%), a positive predictive
value of 78% (95% CI, 69e85%), and a
negative predictive value of 96% (95%
CI, 94e98%) (Table 2). The positive
predictive value increased to 84% if the
psoriasis question was combined with
the additional question, “Have you
been diagnosed with psoriasis by a
dermatologist?”
Four participants diagnosed with
psoriasis in the period between the
HUNT3 and the validation study were
classified as true negatives. True-
positive participants (n ¼ 86) had a
mean psoriasis area and severity index
of 2.9, whereas false-negative partici-
pants (n ¼ 16) had a mean psoriasis
area and severity index of 0.9. Among
false-negative participants, most had
scalp psoriasis only (n ¼ 12). The group
of false positives (n ¼ 24) consisted of
subjects whose history of psoriasis
could not be verified by a dermatologist
or pathologist (n ¼ 10); people with
unspecified dermatitis (n ¼ 5), benign
skin tumors (n ¼ 2), and urticaria
(n ¼ 1); and 6 individuals without any
history of psoriasis or other relevantwww.jidonline.org 323
Table 1. Self-reported and validation-based prevalence estimates (%) of
psoriasis in the HUNT3 study (2006e8)
Self-reported Validation-based
Prevalence estimate 95% CI Prevalence estimate 95% CI
Total HUNT3 5.8 5.6e6.0 8.0 6.4e9.9
Total HUNT31 NA NA 5.2 4.3e6.2
Men 6.0 5.7e6.4 9.3 6.7e12.8
Women 5.5 5.3e5.8 7.0 5.2e9.3
20e40 y 3.8 3.5e4.2 6.1 3.4e10.8
40e60 y 6.4 6.1e6.8 8.9 6.5e12.1
60þ y 6.2 5.9e6.6 8.1 5.6e11.6
1Excluding subjects with scalp psoriasis only. NA, not applicable.
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324dermatological disease. The age-
standardized validation-based preva-
lence estimate according to the Euro-
pean standard population distribution
for adults > 20 years was 8.0% (Pace
et al., 2013).
Major strengths of this study are the
random selection of participants from a
large population-based study (HUNT3)
and the clinical interview and skin ex-
amination carried out by dermatologists
to confirm the diagnosis. Consequently,
we were able to measure the full
spectrum of diagnostic test validity,
including the specificity, sensitivity, and
positive and negative predictive values,
as well as estimate the “true” preva-
lence in a general population.
Compared with most previous
studies, the estimated prevalence of
psoriasis in this study is high (Parisi
et al., 2013). This is in part due to
detection of previously undiagnosed
scalp psoriasis, but it also reflects our
ability to include milder forms of pso-
riasis less often included in hospital-
based samples. Recent prevalence
estimates from Denmark and northern
Norway are in line with our study orTable 2. Validation of self-reported of
Sensitivity
(%)
Estimate 95% CI
Total HUNT3 56 44e68
Total HUNT31 83 65e93
Men 51 35e67
Women 62 44e77
20e40 y 52 25e78
40e60 y 59 40e75
60þ y 56 36e74
1Excluding subjects with scalp psoriasis only.
Journal of Investigative Dermatology (2016), Volumeven higher (Danielsen et al., 2013;
Jensen et al., 2013).
In general, the psoriasis diagnosis is
clinical and based on recognition of
typical psoriatic lesions with a classical
pattern of distribution, but particularly
scalp psoriasis may be challenging to
distinguish from other skin disorders
like seborrheic dermatitis and pityriasis
amiantacea. Of the 16 false-negative
cases, 12 were diagnosed with scalp
psoriasis only. Factors in favor of scalp
psoriasis were a convincing history in
combination with a sharp demarcation
of the psoriasis lesion against normal
skin, positive Auspitz’s sign, and char-
acteristic scaling. A diffuse distribution
in combination with affection of the
eyebrows and nasolabial folds sug-
gested seborrheic dermatitis, whereas
thick scales forming layers along the
hair strands and bundles of hair favored
pityriasis amiantacea. When excluding
subjects with scalp psoriasis only, the
validation based prevalence estimate
was 5.2%.
A limitation to this study is that
dermatologists knew what participants
had answered to the psoriasis questionpsoriasis in HUNT3 (2006e8)
Specificity
(%)
Positive pre
(%
Estimate 95% CI Estimate
99 98e99 78
98 98e99 75
99 98e99 78
99 98e99 78
99 95e100 83
99 98e99 81
98 97e99 73
e 136in HUNT3. Furthermore, any skin
complaint could be a motivation for
participation, and this could potentially
have led to a bias in the validation-
based prevalence. Still, the risk of
diagnostic misclassification seems
small because the diagnostic inference
was based on a thorough clinical
interview and extensive skin examina-
tion. Of the 24 false-positive cases, 10
subjects had a history of psoriasis
that could not be verified (for example,
guttate psoriasis) and were not included
as cases in the validation-based
prevalence estimate. According to our
findings, major bias because of non-
participation in the validation study
seems unlikely. In addition, the partic-
ipants in HUNT3 are shown to be
fairly representative of a general
Norwegian population (Langhammer
et al., 2012).
This study indicates that self-report
of psoriasis is a valid instrument for
further studies of psoriasis in HUNT3.
Furthermore, it suggests that self-report
of psoriasis may underestimate the
prevalence of psoriasis in a general
population, largely because of a
considerable number of people with
undiagnosed scalp psoriasis. Finally,
this study estimates that almost 1 of 12
in the adult Norwegian population may
have psoriasis.
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)
Negative predictive
value
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Hereditary palmoplantar keratodermas
are a heterogeneous group of keratini-
zation disorders characterized by hy-
perkeratosis of the palms and soles with
or without other ectodermal abnor-
malities. Nagashima-type palmoplantar
keratosis (NPPK; MIM 615598) is a
recently established autosomal reces-
sive palmoplantar keratoderma caused
by mutations in the gene encoding
SERPINB7, a member of the serineprotease inhibitor superfamily (Kubo,
2014; Kubo et al., 2013). NPPK is
characterized by a well-demarcated
reddish, diffuse, and mild non-
epidermolytic palmoplantar kerato-
derma extending to the dorsal surface
of the hands and feet, inner wrists, and
Achilles tendon area. To date, a highly
prevalent mutation of c.796C>T
(rs142859678; p.R266*) has been re-
ported in 39 of 46 alleles of Japanese
individuals with NPPK, and in 10 of14 alleles of Chinese individuals with
NPPK (Kubo et al., 2013; Mizuno et al.,
2014; Yin et al., 2014). The c.796C>T
mutation was found only among Japa-
nese and Chinese populations but not
Western and African populations in the
1000 Genomes project database (Kubo
et al., 2013). Single nucleotide poly-
morphisms (SNPs) observed within the
SERPINB7 genomic lesion were iden-
tical for the c.796C>T allele in the
Chinese population (Yin et al., 2014),
suggesting a founder effect of the
mutation.
SERPINB7 is expressed in the stratum
granulosum and stratum corneum. Towww.jidonline.org 325
